LLY · News · 20260824N

Products and Technology - Alzheimer’s Blood Test

ELI LILLY & Co · 2026-08-24 · Importance 38 · Surprise 60

Roche and Eli Lilly received U.S. clearance for the Elecsys pTau217 blood test, designed to identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline. The test provides a less invasive diagnostic alternative to PET scans and cerebrospinal-fluid testing and is already approved in Europe. It will use Roche analyzers and laboratory networks including Labcorp and Quest Diagnostics, supporting distribution through established clinical-testing infrastructure.

Key facts

• Roche said the Elecsys pTau217 test will be accessible through existing Roche analyzers and laboratory networks like Labcorp and Quest Diagnostics. source
• The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms that was developed by Roche and Eli Lilly. source
• The FDA has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55. source
• The U.S. FDA cleared Roche and Eli Lilly's Elecsys pTau217 blood test for identifying signs of Alzheimer's disease in individuals aged 55 and older with cognitive decline. source
• The Elecsys pTau217 Alzheimer biomarker test was already approved in Europe before receiving U.S. FDA clearance. source